TY - JOUR
T1 - Medical therapy for ulcerative colitis
AU - Hanauer, S. B.
PY - 2000/12/1
Y1 - 2000/12/1
N2 - Last year was not a banner year for developments in medical therapy for ulcerative colitis. In contrast to the expansion of therapies for Crohn disease, treatment for ulcerative colitis was evolutionary, at best, leading many patients to seek alternative medical approaches. Nevertheless, there have been advances in the application of aminosalicylates and immune modifiers for ulcerative colitis. Additional, nonconventional approaches include nicotine, probiotics, dietary therapies, and heparins. Several novel approaches have arisen from animal models, including additional means of inhibiting nuclear factorκB and targeting of tumor necrosis factor-α.
AB - Last year was not a banner year for developments in medical therapy for ulcerative colitis. In contrast to the expansion of therapies for Crohn disease, treatment for ulcerative colitis was evolutionary, at best, leading many patients to seek alternative medical approaches. Nevertheless, there have been advances in the application of aminosalicylates and immune modifiers for ulcerative colitis. Additional, nonconventional approaches include nicotine, probiotics, dietary therapies, and heparins. Several novel approaches have arisen from animal models, including additional means of inhibiting nuclear factorκB and targeting of tumor necrosis factor-α.
UR - http://www.scopus.com/inward/record.url?scp=0034465027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034465027&partnerID=8YFLogxK
U2 - 10.1097/00001574-200007000-00006
DO - 10.1097/00001574-200007000-00006
M3 - Article
C2 - 17031096
AN - SCOPUS:0034465027
SN - 0267-1379
VL - 16
SP - 324
EP - 328
JO - Current Opinion in Gastroenterology
JF - Current Opinion in Gastroenterology
IS - 4
ER -